OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 18, 2021
An integrated CMC provider can help smaller companies to streamline development timelines and reduce project management complexity when compared with multi-provider models.
The Testa Center in Sweden provides access to equipment and expertise to help bridge the gap between biopharmaceutical discovery and industrialization.
March 17, 2021
Sana will be authorized to use the iPSC cell lines from FUJIFILM Cellular Dynamics for the research and development, clinical and commercial manufacture, and commercialization, of the cell therapies derived from the lines.
March 16, 2021
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
March 15, 2021
Continuus Pharmaceuticals is building the first GMP facility using integrated continuous manufacturing technology for end-to-end production of small-molecule APIs and finished dosage forms.
March 11, 2021
Through the acquisition, Takeda will have access to Maverick’s T-cell engager COBRA platform, along with its development portfolio.
March 03, 2021
In a pandemic, genetic vaccines offer several advantages over traditional approaches.
Without an independent approval pathway for novel excipients, true pharmaceutical innovation could be stymied.
Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.
March 02, 2021
FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.